TCGA-UY-A8OC-01A-11R-A36F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.650
- ANGIOGENESIS+0.600
- HEDGEHOG_SIGNALING+0.510
- TGF_BETA_SIGNALING+0.500
- HYPOXIA+0.410
- NOTCH_SIGNALING+0.410
- APICAL_JUNCTION+0.390
- COAGULATION+0.390
- GLYCOLYSIS+0.320
- KRAS_SIGNALING_UP+0.300
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.440
- INTERFERON_GAMMA_RESPONSE-0.360
- BILE_ACID_METABOLISM-0.310
- FATTY_ACID_METABOLISM-0.260
- KRAS_SIGNALING_DN-0.200
- PEROXISOME-0.180
- SPERMATOGENESIS-0.150
- ESTROGEN_RESPONSE_LATE-0.090
- MYC_TARGETS_V2-0.090
- G2M_CHECKPOINT-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-01838 | — | cohortSQ1 | 0.854 |
| 2 | TCGA-77-8130-01A-11R-2247-07 | — | cohortSQ1 | 0.839 |
| 3 | BS_KP735TJ6 | high-grade glioma | — | 0.832 |
| 4 | SRR8943050 | — | — | 0.830 |
| 5 | TCGA-BL-A5ZZ-01A-31R-A30C-07 | — | — | 0.795 |
| 6 | SRR12696782 | — | — | 0.790 |
| 7 | R211 | — | — | 0.788 |
| 8 | TCGA-AN-A0AS-01A-11R-A00Z-07 | — | C | 0.777 |
| 9 | ERR2208939 | — | — | 0.776 |
| 10 | TCGA-E2-A152-01A-11R-A12D-07 | — | C | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.650 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.510 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.500 | Inavolisib | — uncovered |
| HYPOXIA | 0.410 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.390 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.270 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.260 | Inavolisib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |